Raltitrexed is a quinazoline analog of folate. Raltitrexed acts as an antifolate anticancer chemotherapeutic, inhibiting thymidylate synthase. Raltitrexed disrupts DNA synthesis and induces strand breaks. This compound is approved in some countries for the treatment of advanced colorectal cancer.
| Cas No. | 112887-68-0 |
|---|---|
| Purity | ≥98% |
| Formula | C21H22N4O6S |
| Formula Wt. | 458.49 |
| Chemical Name | (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid |
| IUPAC Name | (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino] thiophene-2-carbonyl]amino]pentanedioic acid |
| Melting Point | 180-184°C |
| Appearance | White to light yellow powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Avallone A, Gennaro ED, Silvestro L, et al. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf. 2014 Jan;13(1):113-29. PMID: 24093908.
Van Cutsem E, Cunningham D, Maroun J, et al. Raltitrexed: current clinical status and future directions. Ann Oncol. 2002 Apr;13(4):513-22. PMID: 12056700.
